{"id":"hm11260c","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vaginal dryness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a SERD, HM11260C binds to the estrogen receptor with high affinity and promotes its proteasomal degradation, eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism differs from selective estrogen receptor modulators (SERMs) by achieving complete receptor elimination rather than partial antagonism, potentially overcoming resistance mechanisms in hormone receptor-positive breast cancer.","oneSentence":"HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:55.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT07379333","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","status":"NOT_YET_RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2026-02","conditions":"Type 2 Diabetes","enrollment":118},{"nctId":"NCT06174779","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2024-01-03","conditions":"Obesity","enrollment":420},{"nctId":"NCT02075281","phase":"PHASE2","title":"Effect of LAPS-Exendin on Body Weight in Obese Population","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-02","conditions":"Obesity","enrollment":297},{"nctId":"NCT01452451","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2011-12","conditions":"Diabetes Mellitus","enrollment":72},{"nctId":"NCT02081118","phase":"PHASE2","title":"Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-02","conditions":"Type 2 Diabetes","enrollment":209},{"nctId":"NCT02057172","phase":"PHASE2","title":"Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":254},{"nctId":"NCT02059564","phase":"PHASE1","title":"A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2013-12","conditions":"Diabetes Mellitus","enrollment":44},{"nctId":"NCT01093729","phase":"PHASE1","title":"A Study of HM11260C in Healthy Male Subject","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2010-02","conditions":"Healthy","enrollment":41}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LAPS-Exendin-4","LAPS-Exendin4"],"phase":"phase_3","status":"active","brandName":"HM11260C","genericName":"HM11260C","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HM11260C is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Hormone receptor-positive, HER2-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}